Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer

e12079 Background: The expression status of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 antigen (Ki-67) divides breast cancer into different subtypes. Changes in these biomarkers during treatment alter the overall treatment decision and affect prognosis. To date, few studies have investigated the effects of changes in these biomarkers throughout neoadjuvant chemotherapy (NAC) on patient prognosis. Methods: A total of 482 patients who received NAC were enrolled. The expression of ER, PR and Ki-67 between pre- and posttherapy specimens was studied by immunohistochemical methods. Physical and imaging examinations based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 were utilized to assess the treatment response. The impact of these biomarkers status changes on survival was then tested for statistical significance using a Cox proportional hazards regression model for univariate and multivariate analyses. Results: The rate of discordance for ER, PR and Ki-67 was 10.37%, 17.01% and 77.39%, respectively, in which the PR positive-to-negative conversion was the most common change. A statistically significant differential overall survival (OS) related to biomarkers status throughout NAC (P<.01) was noted. The risk of death in patients with a PR positive-to-negative conversion was 6.58 times greater than that of stable PR expression (P=.002). The risk of disease recurrence in patients with increased Ki-67 expression was 1.91 times greater than that of stable Ki-67 expression (P=.02). Furthermore, we validated both of them as independent predictors of poor prognosis. Conclusions: We concluded that inconsistent expression of biomarkers can significantly affect patient prognosis. We suggest that biomarkers investigations during NAC may potentially improve patient management and survival. Survival result that compared with concordance and discondance in ER, PR and Ki-67. (N=482).*P<.05. [Table: see text]

Download Full-text

Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer

Chinese Medical Journal ◽

10.1097/00029330-201409200-00015 ◽

2014 ◽

Vol 127 (18) ◽

pp. 3272-3277 ◽

Cited By ~ 5

Author(s):

Qin Qinghong ◽

Gao Fangfang ◽

Jiang Wei ◽

Tan Qixing ◽

Mo Qinguo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Progesterone Receptor ◽

Growth Factor Receptor ◽

Ki 67 ◽

Epidermal Growth

Download Full-text

Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer

Journal of Oncology ◽

10.1155/2019/7386734 ◽

2019 ◽

Vol 2019 ◽

pp. 1-8

Author(s):

Young-Joon Kang ◽

Han-Byoel Lee ◽

Yun Gyoung Kim ◽

JaiHong Han ◽

Yumi Kim ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Prognostic Factor ◽

Progesterone Receptor ◽

Cancer Patients ◽

Early Breast Cancer ◽

Receptor Expression ◽

Breast Cancer Patients ◽

Ki 67 ◽

End Point

Objective. While the value of Ki-67 has been recognized in breast cancer, controversy also exists. The goal of this study is to show the prognostic value of Ki-67 according to progesterone receptor (PgR) expression in patients who have estrogen receptor- (ER-) positive, human epidermal growth factor receptor 2- (HER2-) negative early breast cancer. Methods. The records of nonmetastatic invasive breast cancer patients who underwent surgery at a single institution between 2009 and 2012 were reviewed. Primary end point was recurrence-free survival (RFS), and secondary end point was overall survival (OS). Ki-67 and PgR were assessed with immunohistochemistry for the tumor after surgery. Results. A total of 1848 patients were enrolled in this study. 223 (12%) patients had high (≥10%) Ki-67, and 1625 (88%) had low Ki-67 expression. Significantly worse RFS and OS were observed in the high vs. low Ki-67 expression only when the PgR was low (<20%) (p<0.001 and 0.005, respectively, for RFS and OS). There was no significant difference in RFS and OS according to Ki-67 when the PgR was high (p=0.120 and 0.076). RFS of four groups according to high/low Ki-67 and PgR expression was compared. The low PgR and high Ki-67 expression group showed worst outcome among them (p<0.001). In a multivariate analysis, high Ki-67 was an independent prognostic factor when the PgR was low (HR 3.05; 95% CI 1.50–6.19; p=0.002). Conclusions. Ki-67 had a value as a prognostic factor only under low PgR expression level in early breast cancer. PgR should be considered in evaluating the prognosis of breast cancer patients using Ki-67.

Download Full-text

Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy

The Breast ◽

10.1016/j.breast.2008.04.002 ◽

2008 ◽

Vol 17 (5) ◽

pp. 523-527 ◽

Cited By ~ 40

Author(s):

Masako Kasami ◽

Takayoshi Uematsu ◽

Masatake Honda ◽

Tsugumi Yabuzaki ◽

Junichi Sanuki ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Chemotherapy ◽

Progesterone Receptor ◽

Her 2

Download Full-text

Breast cancer after IVF: Can ovary stimulation and follicular response affect prognostic factors?

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12538 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12538-e12538

Author(s):

Maxim Izquierdo ◽

Sonia Baulies ◽

Marta Devesa ◽

Fransec Tresserra ◽

Carmen Ara ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Prognostic Factors ◽

Progesterone Receptor ◽

Ovarian Response ◽

Histologic Grade ◽

Breast Cancer Patients ◽

Normal Response ◽

Ki 67 ◽

Follicular Response

e12538 Background: The ovary stimulation and the follicular response is related with estradiol level. Study in breast cancer patients after IVF if ovarian response or number of IVF cycles affects the prognostic factors. Methods: Patients with breast cancer who underwent IVF are studied the prognostic factors (Ki67, HER2, estrogen receptor (ER), progesterone receptor (PR), oncogene p53, histologic grade) in relation to the ovary response and number of IVF cycles. Results: 73 patients with breast cancer after IVF are studied. They performed 135 cycles of IVF, 36 (49’3%) with 1 IVF and 37 (50’7%) with more than one IVF. Hyper response was present in at least one IVF in 24 (32.9%) patients and there was no hyper response in any IVF in 49 (67.1%) patients. The prognostic factors were: Ki 67> 20 in 31'91% (15/47) Ki 67 <20 in 68'08% (32/47), HER2 + 31'94% (23/72) HER2- 68'05% (49/72), p53 + 45'09% (23/51), p53-54'90% (28/51), HG II-III 56'36% (31/55), HG I 43'63% ( 24/55), RE + 87'5% (63/72), RE- 12'5% (9/72), RP + 76'38% (55/72), RP- 23'61% (17/72). None of prognostic factors varied with the ovary response (hyper response in at least one IVF cycle, normal response, normal or low response) (p=ns). The only prognostic factor that varied with the IVF number was p53 +. Patients with p53 + (23/51), 7 (30’43%) has one IVF, and 16 (69’53%) have more one IVF (p<0’05). Conclusions: In breast cancer after IVF, the ovary stimulation and the follicular response not affect Ki67, HER2, estrogen receptor, progesterone receptor, p53, and histologic grade. p53 positive is more frequent in patients with more than one IVF.

Download Full-text